Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II (POEMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01451723
Recruitment Status : Terminated (Unusual high frequency of elevated liver function tests.)
First Posted : October 14, 2011
Results First Posted : March 14, 2014
Last Update Posted : March 14, 2014
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Jesus Lovera MD, Louisiana State University Health Sciences Center in New Orleans

October 11, 2011
October 14, 2011
December 10, 2013
March 14, 2014
March 14, 2014
July 2011
February 2013   (Final data collection date for primary outcome measure)
Rate of Change in NAA Levels Adjusted for Water Content. [ Time Frame: 1 year ]
The rate of change will be calculated using all the time points available )baseline, 6 and 12 months) using a mixed model analysis with the Log NAA as the dependent variable and water content, %grey matter, %white matter, %CSF and % lesion volume as covariates. All the voxels available for each subject where estimates have a SD <30 will be used. A spatial anysotropic exponential covariance structure will be used.
Same as current
Complete list of historical versions of study NCT01451723 on Archive Site
Brain Atrophy [ Time Frame: 1 year ]
Difference between the two groups in brain atrophy as measured by SIENA
Same as current
Not Provided
Not Provided
Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II
Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS
The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons and their metabolism) over one year between people with MS treated with Polyphenon E at a dose of 400mg twice a day and people with MS treated with a matching sugar pill.

This will be a double blind placebo controlled trial of Polyphenon E as a treatment for MS.

The primary outcome will be the changes in NAA levels over one year. Secondary outcomes will be changes in brain atrophy over one year. As an exploratory outcome we will correlate changes in NAA levels with free Plasma levels of EGCG 8 hours after the morning dose.

Exploratory outcomes include disability progression by EDSS, MS functional composite components and a cognitive test battery.

Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Multiple Sclerosis
  • Drug: Polyphenon E
    Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
    Other Names:
    • EGCG
    • epigallocatechin gallate
    • Green tea extract
  • Other: Placebo
    Matching placebo capsules
  • Experimental: Polyphenon E 400mg twice a day
    Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
    Intervention: Drug: Polyphenon E
  • Placebo Comparator: Placebo
    Matching placebo capsules.
    Intervention: Other: Placebo
Lovera J, Ramos A, Devier D, Garrison V, Kovner B, Reza T, Koop D, Rooney W, Foundas A, Bourdette D. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies. J Neurol Sci. 2015 Nov 15;358(1-2):46-52. doi: 10.1016/j.jns.2015.08.006. Epub 2015 Aug 7.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2013
February 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of MS by McDonald criteria
  • Relapsing-remitting MS or secondary progressive MS
  • Stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six months
  • EDSS Score less than or equal to 7.0
  • Ages 18-60.
  • Participants must have normal organ and marrow function as defined below:

    1. Leukocytes ≥3,000/µL
    2. Absolute neutrophil count ≥1,500/µL
    3. Platelets ≥100,000/µL
    4. Total bilirubin ≤local upper limit of normal
    5. AST (SGOT) ≤local upper limit of normal
    6. ALT (SGPT) ≤local upper limit of normal
    7. Creatinine ≤local upper limit of normal

Exclusion Criteria:

  • MS relapse within the 30 days prior to enrollment
  • A primary progressive form of MS.
  • Previous treatment prior to study entry as follows: complete radiation ablation of the bone marrow or anti-CD4 antibody treatment (Campath) at any time; mitoxantrone, cyclophosphamide, Natalizumab or other immunomodulatory or immunosuppressant therapies except the DMT's included in the inclusion criteria and methylprednisone for relapses within prior nine months.
  • History of renal or liver disease.
  • Consumption of green tea or supplements containing green tea or tea extract within 30 days prior to enrollment.
  • Participants may not participate in any other clinical trial involving investigational agents during the study, or within six months prior to enrolling in the study.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Polyphenon E, tea, or any of the inactive ingredients present in the active or placebo capsules, including gelatin.
  • History of allergic reactions to gadolinium or any other condition contraindicated for MRI.
  • Uncontrolled, clinically-relevant active illness (aside from MS) including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study
  • Inability to complete the baseline MRI scan
  • Pregnant women
  • Any underlying predisposition to gastrointestinal bleeding (peptic ulcer disease, gastritis, diverticulitis, colitis, hemorrhoids)
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
K23AT004433-02( U.S. NIH Grant/Contract )
K23AT004433-02 ( U.S. NIH Grant/Contract )
K23AT004433 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Jesus Lovera MD, Louisiana State University Health Sciences Center in New Orleans
Louisiana State University Health Sciences Center in New Orleans
National Center for Complementary and Integrative Health (NCCIH)
Principal Investigator: Jesus F Lovera, MD LSUHSC-New Orleans
Louisiana State University Health Sciences Center in New Orleans
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP